Global Blood Therapeutics: Funding, Investors & Team (Oct 2026)
GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and headquartered in San Francisco, California.
Global Blood Therapeutics has raised $300M across 1 funding round on record, the most recent a Post-IPO Debt of $300M announced in Dec 2021.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Global Blood Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2021.
Global Blood Therapeutics Funding Rounds
Global Blood Therapeutics Founders and Leadership Team
Contact details for the Global Blood Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Global Blood Therapeutics Funding Compared to Other Biotechnology Startups
Global Blood Therapeutics' latest round of $300M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Global Blood Therapeutics in Biotechnology and San Francisco
Companies Similar to Global Blood Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Global Blood Therapeutics Funding FAQs
What does Global Blood Therapeutics do?
GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and headquartered in San Francisco, California.
How much funding has Global Blood Therapeutics raised?
Global Blood Therapeutics has raised $300M across 1 round on record. The most recent is a Post-IPO Debt of $300M announced in Dec 2021.
When did Global Blood Therapeutics last raise funding?
Global Blood Therapeutics' most recent funding round on record is a Post-IPO Debt of $300M, announced in Dec 2021.
Who is the CEO of Global Blood Therapeutics?
Ted W. Love is listed as CEO at Global Blood Therapeutics.
Where is Global Blood Therapeutics headquartered?
Global Blood Therapeutics is based in San Francisco, California, United States.
How many employees does Global Blood Therapeutics have?
Global Blood Therapeutics is in the 251-500 employee band.
How does Global Blood Therapeutics' funding compare to other Biotechnology startups?
Global Blood Therapeutics' latest round of $300M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Global Blood Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Global Blood Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.